Inhibitors against Src [43,44,45,46] and PI3K [47,48,49] have already been in clinical trials for patients with solid tumors and other cancer types such as breast cancer including GDC0941 [50,51], which was used in our study. The gene discussed is SRC; the disease is cancer.